Bio Techne's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bio Techne's ROA in the fourth quarter of 2026?
Bio techne Corp achieved a return on average assets (ROA) of 7.05 % in its fourth quarter of 2026, which is below Bio Techne's average return on assets, which stands at 9.94%.

ROA has improved compared to 4.39% in the third quarter of 2026, due to net income growth.

However, within the Healthcare sector 126 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 1305, from total ROA ranking in the third quarter of 2026 at 1830.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	13.37 %	-3.54 %	-4.85 %	-7.22 %	-4.85 %
Y / Y Net Income Change	-	125.99 %	8.94 %	13.65 %	-
Net Income (TTM) in million	182	110	81	78	73
Return On Assets (TTM)	7.05 %	4.39 %	3.22 %	3.06 %	2.82 %
TECH's Total Ranking	# 1305	# 1830	# 1603	# 1634	# 1221
Total Assets (TTM) in million	2,819	2,551	2,487	2,458	2,487
Seq. Total Assets Change	10.52 %	2.58 %	1.17 %	-1.15 %	-5.96 %
Seq. Net Income Change	7 %	34.3 %	-0.46 %	-	-

TECH's 5 Years Annual ROA >> Back to TECH Management Effectiveness >> Compare TECH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 16
Sector	# 127
Overall	# 876

Return On Assets Statistics
High	Average	Low
19.09 %	9.94 %	2.76 %
(Dec 31 2011)		(Jun 30 2025)

Financial Statements
Bio Techne's Assets	$ 2,819 million	TECH's Balance sheet
Bio Techne's Income	$ 55 million	Quarterly TECH's Income Statement
TECH's Income by Division		See TECH's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	13.37 %	-4.85 %	2.8 %	13.97 %	1.77 %
Total Assets in million	2,819	2,487	2,613	2,542	2,230
Y / Y Net Income Change	147.77 %	-56.34 %	-41.11 %	8.49 %	88.49 %
Net Income in million	182	73	168	285	263
Annual Return On Assets	6.45 %	2.95 %	6.43 %	11.23 %	11.8 %

TECH's 5 Years Annual ROA >> Back to TECH Management Effectiveness >> Compare TECH ROA to its Competitors

Comment on TECH's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA improved to 6.45 % compared to prior year, due to annual net income growth of 147.77 % to $181.86 million, while value of Bio Techne's overall assets grew just by 13.37 % to $2,819.04 million, compared to $2,819.04 a year before.

More Return On Assets Ratios
TECH's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TECH's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TECH's Competitors
Subscribers only: Roa for Bio Techne's Suppliers
Subscribers only: Return On Assets for TECH's Customers

You may also want to know
TECH's Roi	TECH's Inventory Turnover Ratio	TECH's Growth Rates	TECH's Dividend Comparisons
	TECH's Profitability Ratios	TECH's Asset Turnover Ratio	TECH's Dividend Growth
TECH's Roe	TECH's Valuation Ratios	TECH's Financial Strength Ratios	TECH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %
Illumina Inc	12.68 %
Spero Therapeutics Inc	12.57 %
Transmedics Group Inc	12.50 %
Eton Pharmaceuticals Inc	12.37 %
Nephros Inc	12.30 %

Date modified: 2026-08-29T04:46:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.